Antios rocked as hepatitis B safety signal sparks clinical hold, termination of collaboration
Antios rocked as hepatitis B safety signal sparks clinical hold, [...]
Antios rocked as hepatitis B safety signal sparks clinical hold, [...]
CSL Behring gene therapy makes comeback after hold for FDA [...]
Genocea closes up shop after failing to find a buyer, [...]
Manufacturing concerns sideline INmune’s US Alzheimer’s trial aarmstrong Tue, 05/24/2022 [...]
Moderna tunes vaccine platform to next potential viral threat: monkeypox [...]
Innoviva buys struggling antibiotic biotech Entasis, as the AstraZeneca spin [...]
Biohaven flunks first clinical test for rare disease drug post-Pfizer [...]
Zymeworks rejects All Blue’s $773M offer as an ‘opportunistic’ public [...]
Not an ‘excellent outcome’ for Athersys stock as stem cell [...]
100% overall survival data for gene therapy fuel Rocket for [...]